GH Research PLC (GHRS) has promoted Velichka “Villy” Valcheva to the position of Chief Executive Officer, succeeding co-founder Theis Terwey. Valcheva brings over two decades of leadership experience in the pharmaceutical and biotech sectors. She joined GH Research in August 2023 and has been serving as Chief Medical Officer since February 2024.In her new role as CEO, Valcheva stated, “Since joining GH Research, I have relentlessly pursued the potential of our product candidates to aid patients suffering from depression. As we continue screening the remaining patients for our phase 2b trial addressing treatment-resistant depression, we anticipate completing enrolment by September this year. Furthermore, our phase 1 healthy volunteer study, utilizing our proprietary device, is actively enrolling participants in the UK.”The material has been provided by InstaForex Company – www.instaforex.com
- Roche’s Xofluza Reduces Influenza Transmission In Phase III Study - September 19, 2024
- UK Car Registrations Plummet in August, Marking a Sharp Year-over-Year Decline - September 19, 2024
- Germany’s Car Registrations Plummet by Nearly 28% Year-Over-Year in August 2024 - September 19, 2024
